Last year, biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) did not disappoint its shareholders. The drugmaker put up an impressive performance that easily exceeded that of the broader market. But that was last year.

The good news for investors is that the company has developments that could lead to a similarly strong showing in 2023. And even at current levels, Vertex is an excellent biotech stock to buy. Let's look into why the drugmaker is such a solid company to invest in now.

VRTX data by YCharts.

Continue reading

Source Fool.com